Significant renoprotective effect of telbivudine during preemptive antiviral therapy in advanced liver cancer patients receiving cisplatin-based chemotherapy: a case–control study

References

• Yeh CT, Chien RN, Chu CM, Liaw YF. Clearance of the original hepatitis B virus YMDD-motif mutants with emergence of distinct lamivudine-resistant mutants during prolonged lamivudine therapy. Hepatology 2000;31:1318–26.
   PubMed Web of Science ®Google Scholar
• Ito K, Arai M, Imazeki F, Yonemitsu Y, Bekku D, Kanda T, et al. Risk of hepatocellular carcinoma in patients with chronic hepatitis B virus infection. Scand J Gastroenterol 2010;45:243–9.
   PubMed Web of Science ®Google Scholar
• Tan TL, Chen WN. A proteomics analysis of cellular proteins associated with HBV genotype-specific HBX: potential in identification of early diagnostic markers for HCC. J Clin Virol 2005;33:293–8.
   PubMed Web of Science ®Google Scholar
• Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010;127:2893–917.
   PubMed Web of Science ®Google Scholar
• Yeh CT, Chen HC, Sung CM, Hsu CL, Lin CC, Pan KT, et al. Retrospective comparison between a regular and a split-dose protocol of 5-fluorouracil, cisplatin, and mitoxantrone for the treatment of far advanced hepatocellular carcinoma. BMC Cancer 2011;11:117.
   PubMed Web of Science ®Google Scholar
• Sohn W, Paik YH, Lee MW, Rhim H, Lim HK, Cho JY, et al. Predisposing factors for recurrence of HBV-related small hepatocellular carcinoma after percutaneous radiofrequency ablation. Scand J Gastroenterol 2014;49:373–80.
   PubMed Web of Science ®Google Scholar
• Bruix J, Sherman M. Management of hepatocellular carcinoma. Hepatology 2005;42:1208–36.
   PubMed Web of Science ®Google Scholar
• Tziomalos K. Effect of antiviral treatment on the risk of hepatocellular carcinoma in patients with chronic hepatitis B. World J Hepatol 2010;2:91–3.
   PubMedGoogle Scholar
• Liang KH, Lin CC, Yeh CT. GALNT14 SNP as a potential predictor of response to combination chemotherapy using 5-FU, mitoxantrone and cisplatin in advanced HCC. Pharmacogenomics 2011;12:1061–73.
   PubMed Web of Science ®Google Scholar
• Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008;359:378–90.
   PubMed Web of Science ®Google Scholar
• Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009;10:25–34.
   PubMed Web of Science ®Google Scholar
• Kohrt HE, Ouyang DL, Keeffe EB. Systematic review: lamivudine prophylaxis for chemotherapy-induced reactivation of chronic hepatitis B virus infection. Aliment Pharmacol Ther 2006;24:1003–16.
   PubMed Web of Science ®Google Scholar
• Loomba R, Rowley A, Wesley R, Liang TJ, Hoofnagle JH, Pucino F, et al. Systematic review: the effect of preventive lamivudine on hepatitis B reactivation during chemotherapy. Ann Intern Med 2008;148:519–28.
   PubMed Web of Science ®Google Scholar
• Guo X, Nzerue C. How to prevent, recognize, and treat drug-induced nephrotoxicity. Cleve Clin J Med 2002;69:289–90; 93–4, 96–7 passim.
   PubMed Web of Science ®Google Scholar
• dos Santos NA, Carvalho Rodrigues MA, Martins NM, dos Santos AC. Cisplatin-induced nephrotoxicity and targets of nephroprotection: an update. Arch Toxicol 2012;86:1233–50.
   PubMed Web of Science ®Google Scholar
• Han X, Yue J, Chesney RW. Functional TauT protects against acute kidney injury. J Am Soc Nephrol 2009;20:1323–32.
   PubMed Web of Science ®Google Scholar
• Zheng XY, Wei RB, Tang L, Li P, Zheng XD. Meta-analysis of combined therapy for adult hepatitis B virus-associated glomerulonephritis. World J Gastroenterol 2012;18:821–32.
   PubMed Web of Science ®Google Scholar
• Chan HL, Chen YC, Gane EJ, Sarin SK, Suh DJ, Piratvisuth T, et al. Randomized clinical trial: efficacy and safety of telbivudine and lamivudine in treatment-naive patients with HBV-related decompensated cirrhosis. J Viral Hepat 2012;19:732–43.
   PubMed Web of Science ®Google Scholar
• Wang Y, Thongsawat S, Gane EJ, Liaw YF, Jia J, Hou J, et al. Efficacy and safety of continuous 4-year telbivudine treatment in patients with chronic hepatitis B. J Viral Hepat 2013;20:e37–46.
   PubMed Web of Science ®Google Scholar
• Lin CL, Chien RN, Hu CC, Lai MW, Yeh CT. Identification of hepatitis B virus rtS117F substitution as a compensatory mutation for rtM204I during lamivudine therapy. J Antimicrob Chemother 2012;67:39–48.
   PubMed Web of Science ®Google Scholar
• Hsu CW, Yeh CT, Chang ML, Liaw YF. Identification of a hepatitis B virus S gene mutant in lamivudine-treated patients experiencing HBsAg seroclearance. Gastroenterology 2007;132:543–50.
   PubMed Web of Science ®Google Scholar
• Lin CL, Chien RN, Lin SM, Ke PY, Lin CC, Yeh CT. An occult hepatitis B-derived hepatoma cell line carrying persistent nuclear viral DNA and permissive for exogenous hepatitis B virus infection. PLoS One 2013;8:e65456.
   Web of Science ®Google Scholar
• Woo G, Tomlinson G, Nishikawa Y, Kowgier M, Sherman M, Wong DK, et al. Tenofovir and entecavir are the most effective antiviral agents for chronic hepatitis B: a systematic review and Bayesian meta-analyses. Gastroenterology 2010;139:1218–29.
   PubMed Web of Science ®Google Scholar
• Biselli M, Andreone P, Gramenzi A, Trevisani F, Cursaro C, Rossi C, et al. Transcatheter arterial chemoembolization therapy for patients with hepatocellular carcinoma: a case-controlled study. Clin Gastroenterol Hepatol 2005;3:918–25.
   PubMed Web of Science ®Google Scholar
• Greten TF, Papendorf F, Bleck JS, Kirchhoff T, Wohlberedt T, Kubicka S, et al. Survival rate in patients with hepatocellular carcinoma: a retrospective analysis of 389 patients. Br J Cancer 2005;92:1862–8.
   PubMed Web of Science ®Google Scholar
• Huang YH, Wu JC, Chen SC, Chen CH, Chiang JH, Huo TI, et al. Survival benefit of transcatheter arterial chemoembolization in patients with hepatocellular carcinoma larger than 10 cm in diameter. Aliment Pharmacol Ther 2006;23:129–35.
   PubMed Web of Science ®Google Scholar
• Wang D, Lippard SJ. Cellular processing of platinum anticancer drugs. Nat Rev Drug Discov 2005;4:307–20.
   PubMed Web of Science ®Google Scholar
• Pabla N, Dong Z. Cisplatin nephrotoxicity: mechanisms and renoprotective strategies. Kidney Int 2008;73:994–1007.
   PubMed Web of Science ®Google Scholar
• Arany I, Safirstein RL. Cisplatin nephrotoxicity. Semin Nephrol 2003;23:460–4.
   PubMed Web of Science ®Google Scholar
• Liang K-H, Chen Y-C, Hsu C-W, Chang M-L, Yeh C-T. Decrease of serum angiotensin converting enzyme levels upon telbivudine treatment for chronic hepatitis B virus infection and negative correlations between the enzyme levels and estimated glumerular filtration rates. Hepat Mon 2014;14:e15074.
   Web of Science ®Google Scholar